20:14 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Opko's diabetes therapy meets in Phase IIb

Opko said OPK88003 met the primary endpoint in a Phase IIb trial to treat adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK)...
21:11 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest an inactivated influenza virus vaccine expressing monoglycosylated HA could help prevent infection by multiple influenza A virus strains. The vaccine consists of inactivated H1N1 influenza virus particles modified to...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
15:58 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Opko raises $92.5M in private placement

Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) raised $92.5 million in a private placement on Nov. 8 through the sale of 26.5 million shares at $3.49. The price is a 10% discount to Opko's close of...
23:20 , Sep 7, 2018 |  BC Extra  |  Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

The SEC filed charges against biotech investor and former Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Chairman Phillip Frost alleging that he participated in “pump-and-dump” schemes involving penny stock companies. Frost, who is chairman and CEO at...
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
05:15 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

Tesaro Inc. (NASDAQ:TSRO) issued a Dear Health Care Provider letter for Varubi rolapitant IV (SCH 619734) saying that anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some of...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
19:57 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest endosome-targeting conjugates of CRLR and NK1R antagonists could help treat chronic pain. The conjugates were created by linking CRLR and NK1R antagonist tool compounds to the lipid cholestanol, which targets...
19:00 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

FDA approves Tesaro's Varubi rolapitant IV to prevent CINV

On Oct. 25, FDA approved a resubmitted NDA for Varubi rolapitant IV from Tesaro Inc. (NASDAQ:TSRO) in combination with other antiemetic agents to prevent delayed chemotherapy-induced nausea and vomiting (CINV). Tesaro expects to launch the...